LIF and Autoimmunity: Since LIF opposes TH17 immunity, the concept of dual therapy – i.e., treating with alemtuzumab, followed by LIF-NP during homeostatic recovery phase – may enhance self-tolerant immunity and avoid secondary autoimmunity as the recovering T cell repertoire matures.